LINK TO ONE OF OUR 52 MEMBER COUNTRIES FOR LOCAL SUPPORT, ADVICE AND NEWS

view map
close
  • Finland
  • Norway
  • Sweden
  • Estonia
  • Russian Federation
  • Latvia
  • Denmark
  • Lithuania
  • United Kingdom
  • Netherlands
  • Ireland
  • Poland
  • Germany
  • Belgium
  • Czech Republic
  • Ukraine
  • Slovakia
  • Luxembourg
  • Moldova, Republic of
  • Austria
  • France
  • Switzerland
  • Romania
  • Slovenia
  • Croatia
  • Serbia
  • Bosnia & Herzegovina
  • Bulgaria
  • Italy
  • Macedonia, the Former Yugoslav Republic of
  • Spain
  • Greece
  • Israel

AVROBIO Explore Gene Therapy As a Potential Treatment For Gaucher Disease

10 April 2019

The IGA are excited to be working in partnership with Avrobio to explore gene therapy as a potential treatment for Gaucher patients.  

AVROBIO, a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose.
 
Gene therapy involves the transplantation of normal genes into cells in order to correct genetic disorders. Gene therapy uses a vector (see illustration below) to carry and deliver a working copy of a gene to the body’s cells. A vector is a deactivated virus that is unable to reproduce and spread (#1 below). There are different types of vectors. AVROBIO’s plato™ is a gene therapy platform which uses a lentiviral vector and is designed to target underlying genetic disease by restoring normal gene function (#2 below) and enzyme production.

 

For more information about AVROBIO's pipeline and technology, please visit their website